Comparative Pharmacology
Head-to-head clinical analysis: PLENAXIS versus SPIRONOLACTONE W HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLENAXIS versus SPIRONOLACTONE W HYDROCHLOROTHIAZIDE.
PLENAXIS vs SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective androgen receptor modulator (SARM); binds to androgen receptors with high affinity, activating anabolic signaling pathways in muscle and bone with reduced androgenic effects on prostate and skin.
Spironolactone is a potassium-sparing diuretic that competitively inhibits aldosterone binding to mineralocorticoid receptors in the distal convoluted tubule, reducing sodium reabsorption and potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Initial: 10 mg orally once daily, titrated to blood pressure and heart rate response; maintenance: 20-80 mg daily in 1-2 divided doses.
Oral: 1-4 tablets daily, each tablet containing spironolactone 25 mg and hydrochlorothiazide 25 mg. Typically once or twice daily with meals.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours in healthy adults; clinically significant accumulation occurs in renal impairment (CrCl <30 mL/min) with half-life prolonged to 40-60 hours.
Spironolactone: Terminal half-life 1.4 hours (parent drug); active metabolite canrenone has half-life 16.5 hours, leading to prolonged effects. Hydrochlorothiazide: Terminal half-life 6–15 hours (average 10 hours), extended in renal impairment.
Renal: 70% as unchanged drug; fecal: 10% as metabolites; biliary: 5% as unchanged drug and metabolites.
Spironolactone: Renal (about 50% as metabolites, <10% as unchanged drug) and biliary/fecal (remainder). Hydrochlorothiazide: Renal (≥95% as unchanged drug via tubular secretion).
Category C
Category D/X
Aldosterone Antagonist
Aldosterone Antagonist